These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 12691600)

  • 21. [Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
    Philipp M; Lesch OM; Schmauss M; Dose M; Glaser T
    Psychiatr Prax; 2003 May; 30 Suppl 2():S94-6. PubMed ID: 14509050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Utilisation of atypical antipsychotic drugs in institutionalised elderly persons and prevalence of metabolic alterations].
    Martínez Romero G; Peris Martí JF; Gomar Fayos J; Navarro Gosalbez M; Quintana Vargas I; Muelas Tirado J
    Farm Hosp; 2010; 34(3):139-47. PubMed ID: 20434929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind pilot study of risperidone in the treatment of conduct disorder.
    Findling RL; McNamara NK; Branicky LA; Schluchter MD; Lemon E; Blumer JL
    J Am Acad Child Adolesc Psychiatry; 2000 Apr; 39(4):509-16. PubMed ID: 10761354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.
    Troost PW; Lahuis BE; Steenhuis MP; Ketelaars CE; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1137-44. PubMed ID: 16239862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risperidone in pervasive developmental disorders.
    Erickson CA; Stigler KA; Posey DJ; McDougle CJ
    Expert Rev Neurother; 2005 Nov; 5(6):713-9. PubMed ID: 16274329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
    Byerly MJ; Nakonezny PA; Rush AJ
    Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risperidone: new indication. Behavioural disorders in children with autism or mental disabilities: no progress.
    Prescrire Int; 2006 Apr; 15(82):43-5. PubMed ID: 16602211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using the Diagnostic Assessment of the Severely Handicapped-II (DASH-II) to measure the therapeutic effects of risperidone.
    Valdovinos MG; Zarcone JR; Hellings JA; Kim G; Schroeder SR
    J Intellect Disabil Res; 2004 Jan; 48(1):53-9. PubMed ID: 14675232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meige's syndrome associated with risperidone therapy.
    Ananth J; Burgoyne K; Aquino S
    Am J Psychiatry; 2000 Jan; 157(1):149. PubMed ID: 10618045
    [No Abstract]   [Full Text] [Related]  

  • 30. Multimodal evaluation of risperidone for destructive behavior: functional analysis, direct observations, rating scales, and psychiatric impressions.
    Valdovinos MG; Napolitano DA; Zarcone JR; Hellings JA; Williams DC; Schroeder SR
    Exp Clin Psychopharmacol; 2002 Aug; 10(3):268-75. PubMed ID: 12233987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone guidelines.
    Klausner M; Brecher M
    Psychiatr Serv; 1995 Sep; 46(9):950-1. PubMed ID: 7583512
    [No Abstract]   [Full Text] [Related]  

  • 32. Response to "Risperidone and sulpiride: Brands vs generics".
    Hsu CW; Lee SY; Wang LJ
    Schizophr Res; 2018 May; 195():274. PubMed ID: 28844637
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of Diogenes syndrome: clinical and ethical challenges.
    Bonci G; Varghese E; Mahgoub N
    J Am Geriatr Soc; 2012 Sep; 60(9):1780-1. PubMed ID: 22985153
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Thioridazine: re-evaluating the risk/benefit equation.
    Timell AM
    Ann Clin Psychiatry; 2003 Jun; 15(2):131. PubMed ID: 12938870
    [No Abstract]   [Full Text] [Related]  

  • 35. Risperdal advertising in JAGS. Journal of the American Geriatrics Society.
    Beers MH
    J Am Geriatr Soc; 1999 Mar; 47(3):377. PubMed ID: 10078907
    [No Abstract]   [Full Text] [Related]  

  • 36. Choices clinicians must make: when to intervene and how to help.
    Black DW
    Ann Clin Psychiatry; 2011 May; 23(2):81. PubMed ID: 21696007
    [No Abstract]   [Full Text] [Related]  

  • 37. Datapoints: Diabetes prevalence among persons with serious mental illness and developmental disability.
    Lunsky Y; Lin E; Balogh R; Klein-Geltink J
    Psychiatr Serv; 2011 Aug; 62(8):830. PubMed ID: 21807822
    [No Abstract]   [Full Text] [Related]  

  • 38. Risperidone and parent training in pervasive developmental disorders.
    van Haaren F
    J Am Acad Child Adolesc Psychiatry; 2010 Apr; 49(4):406-7; author reply 407-8. PubMed ID: 20410733
    [No Abstract]   [Full Text] [Related]  

  • 39. From the Editor-in-Chief's Desk.
    Koplewicz HS
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):535. PubMed ID: 25514540
    [No Abstract]   [Full Text] [Related]  

  • 40. Antipsychotic nanomedicine: a successful platform for clinical use.
    Muthu MS; Agrawal P; Singh RP
    Nanomedicine (Lond); 2014 Jul; 9(14):2071-4. PubMed ID: 25405791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.